Moreover, in a recent paper, Tschirdewahn and colleagues found that serum IMP3 levels associated with poor survival in renal cell carcinoma (RCC) patients, thus suggesting its role as a biomarker to improve the risk-stratification of RCC patients and to optimise therapeutic and follow-up decisions [17]. This evidence concerns the gene IMP3 and renal cell carcinoma.